Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Alfie post
I view this as being very good news for the SPNG shareholders, albeit perhaps not for the same reasons that many others do.
I have no problems with the company making investment into other companies. However two things bothered me about this particular deal.
The first was that the two companies could never really agree on suitable terms for the investment and secondly I was definitely not enamored with the people involved on the GFGU side of the ledger. They are just not the type of people that I, as a SPNG shareholder, really wanted to be involved with.
GFGU is not a stable company at this point in time. No real revenues and no stability at all. The stock remains quite volatile and this makes the casting of an investment price a very tricky situation because what appears to be a good deal on one day may not look so good the next.
Just look what happened to the GFGU stock price recently to see that is has been all over the place. This is definitely not what you would like to see in a deal where you are investing in return for a sizable stock position.
So bad fundamentals and questionable people involved all added up to a very risky deal for SPNG shareholders and that is whay I say, good riddance to the GFGU deal.
I think short found the bottom and they started covering
Investor hub says I am in Happy hour. WTF
if it goes private then what happens to our share
Soapy who is in the bid right now? is it AYME?
0.093 edit :while typing it is now 0.094
0.0895 hod
what is the pps now
every dog has its day. finally
0.40 good to see this after long time
cuz noone is selling
I hope u r covering. if not u will have to beg for the shares
Are shorts covering?
I am not selling a single share before seeing the 10K. If it is a scam I loose some but if they are what they are saying i am sure it will make hell lot of a money.
No risk No GAIN
they sure have known this issue before the reverse split PR
the company knew that this 10k issue will come up and the reverse split think wouldnt happen and in the mean time they were able to get the cheap shares.
may be the future is good but dont know after all this drama they have created
It has already been ruined. wake up
who is buying a company that cannnot file a 10k
today is the deadline
see page 12 of the pdf
http://www.edgarfilings.biz/calendar/Calendar.pdf
The EDGAR system hours of operation for submitting files are 6:00 a.m. to 10:00 p.m. Eastern Time, weekdays, excluding Federal Holidays. Files submitted after 5:30 p.m. Eastern (with the exception of Section 16 filings) will receive the next business day's filing date.
- Companies may request a filing extension for their Form 10-Q's and 10-K's by submitting Form 12b-25 via the EDGAR system. By filing this form, a filer may gain up to 5 additional days to file Form 10-Q or 15 days to file Form 10-K. Companies have up to 24 hours after the original filing deadline to file Form 12b-25.
Link: http://www.secfile.net/SEC_calendar.htm
So when will we see SPNGE today or tomorrow
AzaSite(R) Production Increased in Response to Erythromycin Ophthalmic Ointment Shortage
Monday 09/14/2009 4:03 PM ET - Businesswire
As of 9:58 AM ET 9/15/09
InSite Vision Incorporated (OTCBB: INSV) today announced that Inspire Pharmaceuticals, its commercial partner for AzaSite(R) (azithromycin ophthalmic solution) 1% in the U.S and Canada, has committed to increasing production of AzaSite in response to the manufacturing supply shortage of erythromycin ophthalmic ointment (0.5%).
Erythromycin ophthalmic ointment is approved for prophylaxis of ophthalmia neonatorum, a form of bacterial conjunctivitis that may be contracted by newborns during delivery. It is the only product approved for this indication commercially available in the United States. Recently, the U.S. Food and Drug Administration (FDA) placed erythromycin ophthalmic ointment on the FDA's Drug Shortage list. The Centers for Disease Control and Prevention (CDC), the U.S. Department of Health and Human Services, the American Academy of Ophthalmology and the FDA all recommend that existing supplies of erythromycin ophthalmic ointment be reserved for the treatment of neonatal prophylaxis use.
These organizations are encouraging healthcare professionals to use alternative drugs, including AzaSite, for the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin, as well as for treatment of post-surgical and posttraumatic events. In addition, the CDC has recommended AzaSite as an acceptable substitute for neonatal prophylaxis use where erythromycin ophthalmic ointment is not available. AzaSite has not been approved by the FDA for the treatment of prophylaxis of ophthalmia neonatorum and no clinical trials have been conducted using AzaSite in this population. This recommendation was based on available AzaSite data on pharmacology and gonococcal microbiologic sensitivity. CDC guidance on the erythromycin ophthalmic ointment shortage may be viewed online at: http://www.cdc.gov/std/treatment/2006/erythromycinOintmentShortage.htm
Approved by the FDA in 2007 for the treatment of bacterial conjunctivitis, AzaSite requires the fewest doses per course of treatment of available ocular antibiotic products in the U.S. AzaSite is formulated with InSite Vision's patented DuraSite(R) technology to enhance the retention time of the therapeutic agents on the surface of the eye leading to increased ocular tissue concentrations. InSite Vision and Inspire Pharmaceuticals entered into a licensing agreement for the commercialization of AzaSite in February 2007.
About AzaSite(R)
AzaSite(R) (azithromycin ophthalmic solution) 1% is indicated for the treatment of bacterial conjunctivitis caused by the following organisms: CDC coryneform group G, Staphylococcus aureus, Streptococcus mitis group, Streptococcus pneumoniae, and Haemophilus influenzae.
Important Safety Information: In clinical trials, the most common ocular adverse event was eye irritation, which occurred in 1% to 2% of patients. The safety and effectiveness of AzaSite in pediatric patients below 1 year of age have not been established. The efficacy of AzaSite in treating bacterial conjunctivitis in pediatric patients one year or older has been demonstrated in controlled clinical trials. Please see full Prescribing Information for AzaSite at www.azasite.com.
About InSite Vision
InSite Vision is committed to advancing new and superior ophthalmologic products for unmet eye care needs. InSite Vision is recognized for the discovery and development of novel ocular pharmaceutical products based on its DuraSite(R) bioadhesive polymer core technology, an innovative platform that extends the duration of drug delivery on the eye's surface, thereby reducing frequency of treatment and improving the efficacy of topically delivered drugs. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite(R) (azithromycin ophthalmic solution) 1% and Besivance(TM) (besifloxacin ophthalmic suspension) 0.6%. AzaSite is approved in the United States and Canada and currently marketed by InSite Vision's partner, Inspire Pharmaceuticals in the United States. InSite Vision has formed multiple strategic licensing and distribution agreements with qualified partners to market AzaSite in select countries in Asia and South America upon regulatory approval in those regions. Besivance was approved by the U.S. Food and Drug Administration in the second quarter 2009 and is being marketed by Bausch & Lomb and Pfizer Inc.
InSite Vision's ophthalmic product development pipeline also includes ISV-502 and additional product candidates leveraging the company's core technologies. For further information on InSite Vision, please visit www.insitevision.com.
Forward Looking Statements
This news release contains certain statements of a forward looking nature relating to future events, including , InSite's plans to advance its ophthalmologic products, the implication that AsaSite will be commercialize in various territories outside the U.S. and Canada upon regulatory approval in those territories, and InSite's corporate goals. Such statements entail a number of risks and uncertainties, including but not limited to: the results of any future clinical trials InSite may initiate; InSite's reliance on third parties for the commercialization of its products; the ability of InSite to enter into corporate collaborations for its product candidates; InSite's ability to expand its product platform to include additional indications; InSite's ability to compete effectively, either alone or through its partners, with other companies offering competing products or treatments; InSite's ability to maintain and develop additional collaborations and commercial agreements with corporate partners, including those with respect to AzaSite; its ability to adequately protect its intellectual property and to be free to operate with regard to the intellectual property of others; and determinations by the FDA. Reference is made to the discussion of these and other risk factors detailed in InSite Vision's filings with the Securities and Exchange Commission, including its annual report on Form 10-K and its quarterly reports on Form 10-Q, under the caption "Risk Factors" and elsewhere in such reports. Any forward looking statements or projections are based on the limited information currently available to InSite Vision, which is subject to change. Although any such forward looking statements or projections and the factors influencing them will likely change, InSite Vision undertakes no obligation to update the information. Such information speaks only as of the date of its release. Actual events or results could differ materially and one should not assume that the information provided in this release is still valid at any later date.
SOURCE: InSite Vision Incorporated
InSite Vision
Louis Drapeau, 510-747-1220
Chief Executive Officer
mail@insite.com
or
Availe Communications
Media inquiries
Ellen Rose, 650-387-8746
i m GREEEEEEEN
it was around 133 mil 30 mins ago
why the spike today
Looking for a 911 trade
I believe in these things but i dont know how good are you at these things. I was not a believer before until someone told about my past and future. The future he has predicted is happening until now.
That rule applies if R/S comes BEFORE applying. they applied on 8/31/2009. call to confirm
The NASDAQ Stock Market
One Liberty Plaza
165 Broadway
New York, NY 10006
Phone: 212-401-8700
from yahoo
I dont think it is AYME that is covering. There is no reason of holding the share price while they are covering. Shorts want to dig the hole as much as they can.
Watching the previous pattern, the last 10Q was filed on april 20 then we had red days until april 29. Are we seeing the same sort of sell off after the 10k.
Did you hire any lawyer to sue SPNG management. LOL